Developer docs
API playgroundTry for free, no card

Search company profiles

Wugen

Full company profile

uuid00003ox

Namestring
Wugen
Legal namestring
Wugen Inc.
Websiteurl
wugen.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Wugen is a clinical-stage biotechnology company founded in 2018 and headquartered in St. Louis, Missouri, with additional operations in San Diego, California. The company develops allogeneic, off-the-shelf cellular therapies for cancer, combining CRISPR/Cas9 gene editing with proprietary manufacturing platforms (most notably the Moneta platform for memory NK cells) to produce fratricide-resistant CAR-T cell therapies and cytokine-induced memory-like (CIML) NK cell therapies from healthy donor cells. This architecture eliminates the 3–4 week autologous manufacturing timeline and the malignant-cell contamination risk inherent in patient-derived products, with cryopreserved off-the-shelf product intended to support on-demand delivery at point-of-care.

The company's lead asset, Soficabtagene Geleucel (Sofi-cel / WU-CART-007), is an allogeneic CD7-targeted CAR-T therapy engineered to delete the CD7 and TRAC genes, currently in pivotal Phase 2 (T-RRex) testing for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). Its second clinical program, WU-NK-101, is a memory NK cell therapy in Phase 1 for AML with solid tumor expansion in development. Sofi-cel has accumulated Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA plus EU PRIME designation; early-phase data show a 91% overall response rate and 72.7% complete remission rate in heavily pretreated patients. Wugen is pre-revenue with a BLA submission targeted for 2027. Revenue mechanics post-approval will rely on direct-to-hospital and specialty treatment center channels, supplemented by an exclusive Asia commercialization partnership with Alpha Biopharma covering mainland China, Hong Kong, Macao, Taiwan, and Singapore, with manufacturing enabled by CDMO partner Cellipont Bioservices and MaxCyte electroporation technology. Core IP is anchored by exclusive licenses from Washington University in St. Louis (DiPersio lab for CAR-T, Fehniger lab for memory NK) and HCW Biologics for fusion protein manufacturing reagents.

Short descriptiontext

Wugen is a clinical-stage biotechnology company developing allogeneic, off-the-shelf CAR-T and memory NK cell therapies for hematologic malignancies and solid tumors, with its lead program Soficabtagene Geleucel in pivotal Phase 2 trials for T-cell leukemia/lymphoma and a BLA submission targeted for 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, CAR-T therapy, cancer immunotherapy, NK cell therapy, gene editing
Industry6 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Oncology Biotechnology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing allogeneic cell therapies. Revenue will be generated through commercialization of approved cell therapy products once regulatory approvals are obtained. The company is focused on achieving BLA submission for WU-CART-007 by 2027.

wugen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Wugen is a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for cancer treatment. Its lead candidate, Soficabtagene Geleucel (Sofi-cel / WU-CART-007), is an allogeneic CD7-targeted CAR-T therapy for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL), and WU-NK-101 is an allogeneic memory natural killer cell therapy for acute myeloid leukemia (AML) and solid tumors. The therapies are enabled by Wugen's proprietary CRISPR/Cas9 gene editing and the Moneta feeder cell-free manufacturing platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 91% overall response rate (10 of 11 evaluable patients) and 72.7% complete remission rate in Phase 1/2 trial for R/R T-ALL/LBL
+4 more records
Product overview1 text field

Wugen is a clinical-stage biotechnology company developing a portfolio of allogeneic, off-the-shelf cell therapies for cancer treatment. The company's platform consists of two lead product candidates: Soficabtagene Geleucel (Sofi-cel/WU-CART-007), an allogeneic CD7-targeted CAR-T cell therapy for T-cell malignancies (T-ALL/LBL), and WU-NK-101, a memory natural killer (NK) cell therapy for acute myeloid leukemia (AML) and solid tumors. These products are enabled by Wugen's proprietary gene editing and cell manufacturing platforms, including CRISPR/Cas9 technology and the Moneta feeder cell-free manufacturing system.

Product and service2 records
1Soficabtagene Geleucel (Sofi-cel / WU-CART-007)
CategoryAllogeneic CAR-T Cell Therapy
Description

An allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy engineered using CRISPR/Cas9 gene editing to delete CD7 and TRAC genes, preventing CAR-T cell fratricide and mitigating graft-versus-host disease risk. Manufactured from healthy donor-derived T cells for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/LBL).

2WU-NK-101
CategoryAllogeneic NK Cell Therapy
Description

An allogeneic memory natural killer (NK) cell therapy utilizing cytokine-induced memory-like (CIML) differentiation, developed using Wugen's proprietary Moneta platform with feeder cell-free manufacturing process for treatment of acute myeloid leukemia (AML) and solid tumors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-03-14
Description

Agreement for clinical manufacture of Wugen's off-the-shelf CAR-T cellular therapies. Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), provides manufacturing services to support clinical development.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-01-30
Description

Strategic platform license for MaxCyte's Flow Electroporation technology and ExPERT platform to support scale-up of clinical and commercial manufacturing of Wugen's allogeneic cell therapies for hematologic and solid tumor cancers.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-03-08
Description

Exclusive license and collaboration agreement for manufacturing, development, and commercialization of Wugen's allogeneic cell products in Asia (mainland China, Hong Kong, Macao, Taiwan region, and Singapore). Alpha Biopharma responsible for development and commercialization including manufacturing, clinical, regulatory, marketing and sales in territory. Profits and losses equally shared.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-02
Description

Exclusive license agreement for use of HCW Biologics' proprietary fusion molecules to manufacture Wugen's cellular therapeutics. HCW oversees manufacturing and supply of fusion proteins; Wugen researches, develops, and commercializes cell therapeutic products worldwide. The molecules enable robust activation and expansion of immune cells to lower cost of goods.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-22
Description

Exclusive license agreement for Memory Natural Killer (NK) Cell-based therapy program. Washington University researchers including Todd Fehniger, M.D., Ph.D. provide ongoing collaboration and scientific support for the development of memory NK cell therapies for AML and solid tumors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-11-13
Description

Exclusive license agreement for CAR-T therapy technologies from the laboratory of John F. DiPersio, M.D., Ph.D. Wugen was founded based on technology licensed from Washington University. The partnership has enabled development of fratricide-resistant allogeneic CAR-T cell therapies for T-cell malignancies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Allogene is a leading allogeneic CAR-T developer with multiple clinical-stage programs targeting hematologic malignancies and solid tumors. Both companies share the allogeneic off-the-shelf CAR-T approach using healthy donor-derived cells, making them direct competitors in the same regulatory and commercial landscape.

TypeDirect peer
Description

Fate Therapeutics develops off-the-shelf NK cell and T-cell therapies using iPSC-derived and engineered cell platforms. Its memory NK cell programs (including FT516 and FT576) directly compete with Wugen's WU-NK-101, and both companies target AML and B-cell malignancies with similar off-the-shelf strategies.

TypeDirect peer
Description

Caribou Biosciences develops allogeneic CAR-T cell therapies using CRISPR-based gene editing technology. Both companies leverage CRISPR platforms for allogeneic CAR-T development, though Caribou focuses on B-cell malignancies with CB-010 while Wugen targets T-cell malignancies with WU-CART-007.

TypeDirect peer
Description

Precision Biosciences develops allogeneic CAR-T therapies using ARCUS gene editing technology for hematologic malignancies and solid tumors. Its lead program PBCAR0191 and PBCAR20A target similar patient populations to Wugen's pipeline, making it a comparable competitor in the allogeneic CAR-T space.

TypeDirect peer
Description

Nkarta develops allogeneic NK cell therapies engineered with CAR constructs and other modifications for hematologic malignancies and autoimmune diseases. Its NKX019 (CD19-targeted NK) and NKX101 programs compete directly with Wugen's memory NK cell approach for hematologic cancer indications.

TypeDirect peer
Description

Cellectis is a clinical-stage allogeneic CAR-T developer using TALEN gene editing technology. Both companies pursue fratricide-resistant approaches and target T-cell malignancies, with Cellectis's UCART7 being a direct competitor to Wugen's WU-CART-007 in T-ALL.

TypeDirect peer
Description

Century Therapeutics develops iPSC-derived allogeneic cell therapies including CAR-T and NK cell programs targeting hematologic malignancies and solid tumors. Its multiplexed gene editing platform is comparable to Wugen's Moneta platform for off-the-shelf cell therapy manufacturing.

TypeBroad incumbent
Description

CRISPR Therapeutics is a clinical-stage gene editing company developing both autologous (CASGEVY, approved for sickle cell disease) and allogeneic CAR-T cell therapies. Its CTX112 program targets B-cell malignancies, representing a broader gene editing player with adjacent allogeneic CAR-T ambitions.

TypeBroad incumbent
Description

Editas Medicine is a clinical-stage gene editing company developing CRISPR-based therapies, including EDIT-301 for sickle cell disease and other hematologic indications. While not focused on allogeneic CAR-T, it represents an adjacent gene editing peer with overlapping platform technology.

TypeRegional player
Description

Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors with Tecelra approved for synovial sarcoma. While focused on autologous TCR-T rather than allogeneic CAR-T, it represents a comparable clinical-stage cell therapy peer targeting hematologic and solid tumor indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wugen

Cell Therapy / Oncology Biotechnologywugen.com

Wugen is a clinical-stage biotechnology company developing allogeneic, off-the-shelf CAR-T and memory NK cell therapies for hematologic malignancies and solid tumors, with its lead program Soficabtagene Geleucel in pivotal Phase 2 trials for T-cell leukemia/lymphoma and a BLA submission targeted for 2027.

What Wugen does

Wugen is a clinical-stage biotechnology company founded in 2018 and headquartered in St. Louis, Missouri, with additional operations in San Diego, California. The company develops allogeneic, off-the-shelf cellular therapies for cancer, combining CRISPR/Cas9 gene editing with proprietary manufacturing platforms (most notably the Moneta platform for memory NK cells) to produce fratricide-resistant CAR-T cell therapies and cytokine-induced memory-like (CIML) NK cell therapies from healthy donor cells. This architecture eliminates the 3–4 week autologous manufacturing timeline and the malignant-cell contamination risk inherent in patient-derived products, with cryopreserved off-the-shelf product intended to support on-demand delivery at point-of-care.

The company's lead asset, Soficabtagene Geleucel (Sofi-cel / WU-CART-007), is an allogeneic CD7-targeted CAR-T therapy engineered to delete the CD7 and TRAC genes, currently in pivotal Phase 2 (T-RRex) testing for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). Its second clinical program, WU-NK-101, is a memory NK cell therapy in Phase 1 for AML with solid tumor expansion in development. Sofi-cel has accumulated Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA plus EU PRIME designation; early-phase data show a 91% overall response rate and 72.7% complete remission rate in heavily pretreated patients. Wugen is pre-revenue with a BLA submission targeted for 2027. Revenue mechanics post-approval will rely on direct-to-hospital and specialty treatment center channels, supplemented by an exclusive Asia commercialization partnership with Alpha Biopharma covering mainland China, Hong Kong, Macao, Taiwan, and Singapore, with manufacturing enabled by CDMO partner Cellipont Bioservices and MaxCyte electroporation technology. Core IP is anchored by exclusive licenses from Washington University in St. Louis (DiPersio lab for CAR-T, Fehniger lab for memory NK) and HCW Biologics for fusion protein manufacturing reagents.

Wugen firmographics

Firmographics
Name
Wugen
Legal name
Wugen Inc.
Website
https://wugen.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Wugen is a clinical-stage biotechnology company developing allogeneic, off-the-shelf CAR-T and memory NK cell therapies for hematologic malignancies and solid tumors, with its lead program Soficabtagene Geleucel in pivotal Phase 2 trials for T-cell leukemia/lymphoma and a BLA submission targeted for 2027.
Ownership category
akta.pro rank

Wugen industry classification

Industry
Product category
Cell Therapy / Oncology Biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Allogeneic cell therapy
  • CAR-T therapy
  • Cancer immunotherapy
  • NK cell therapy
  • Gene editing

Where Wugen is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Wugen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Cell Therapy Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing allogeneic cell therapies. Revenue will be generated through commercialization of approved cell therapy products once regulatory approvals are obtained. The company is focused on achieving BLA submission for WU-CART-007 by 2027.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Wugen product offering

Product offering

Core offering

Wugen is a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for cancer treatment. Its lead candidate, Soficabtagene Geleucel (Sofi-cel / WU-CART-007), is an allogeneic CD7-targeted CAR-T therapy for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL), and WU-NK-101 is an allogeneic memory natural killer cell therapy for acute myeloid leukemia (AML) and solid tumors. The therapies are enabled by Wugen's proprietary CRISPR/Cas9 gene editing and the Moneta feeder cell-free manufacturing platform.

Product overview

Wugen is a clinical-stage biotechnology company developing a portfolio of allogeneic, off-the-shelf cell therapies for cancer treatment. The company's platform consists of two lead product candidates: Soficabtagene Geleucel (Sofi-cel/WU-CART-007), an allogeneic CD7-targeted CAR-T cell therapy for T-cell malignancies (T-ALL/LBL), and WU-NK-101, a memory natural killer (NK) cell therapy for acute myeloid leukemia (AML) and solid tumors. These products are enabled by Wugen's proprietary gene editing and cell manufacturing platforms, including CRISPR/Cas9 technology and the Moneta feeder cell-free manufacturing system.

Differentiator

Problem solved

Functional benefit

Products and services

  • Soficabtagene Geleucel (Sofi-cel / WU-CART-007) An allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy engineered using CRISPR/Cas9 gene editing to delete CD7 and TRAC genes, preventing CAR-T cell fratricide and mitigating graft-versus-host disease risk. Manufactured from healthy donor-derived T cells for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/LBL).
  • WU-NK-101 An allogeneic memory natural killer (NK) cell therapy utilizing cytokine-induced memory-like (CIML) differentiation, developed using Wugen's proprietary Moneta platform with feeder cell-free manufacturing process for treatment of acute myeloid leukemia (AML) and solid tumors.

Quantifiable outcome

  • 91% overall response rate (10 of 11 evaluable patients) and 72.7% complete remission rate in Phase 1/2 trial for R/R T-ALL/LBL
  • +4 more outcomes

Companies that use Wugen

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Wugen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Wugen partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major and core.

  • Cellipont BioservicesmajorStrategic or Co-development Partner · 14 March 2024Agreement for clinical manufacture of Wugen's off-the-shelf CAR-T cellular therapies. Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), provides manufacturing services to support clinical development.
  • MaxCytemajorTechnology or Integration · 30 January 2024Strategic platform license for MaxCyte's Flow Electroporation technology and ExPERT platform to support scale-up of clinical and commercial manufacturing of Wugen's allogeneic cell therapies for hematologic and solid tumor cancers.
  • Alpha BiopharmacoreChannel Partner/ Reseller/ Distributor · 8 March 2021Exclusive license and collaboration agreement for manufacturing, development, and commercialization of Wugen's allogeneic cell products in Asia (mainland China, Hong Kong, Macao, Taiwan region, and Singapore). Alpha Biopharma responsible for development and commercialization including manufacturing, clinical, regulatory, marketing and sales in territory. Profits and losses equally shared.
  • HCW BiologicscoreStrategic or Co-development Partner · 2 March 2021Exclusive license agreement for use of HCW Biologics' proprietary fusion molecules to manufacture Wugen's cellular therapeutics. HCW oversees manufacturing and supply of fusion proteins; Wugen researches, develops, and commercializes cell therapeutic products worldwide. The molecules enable robust activation and expansion of immune cells to lower cost of goods.
  • Washington University in St. LouiscoreStrategic or Co-development Partner · 22 February 2021Exclusive license agreement for Memory Natural Killer (NK) Cell-based therapy program. Washington University researchers including Todd Fehniger, M.D., Ph.D. provide ongoing collaboration and scientific support for the development of memory NK cell therapies for AML and solid tumors.
  • Washington University in St. LouiscoreStrategic or Co-development Partner · 13 November 2018Exclusive license agreement for CAR-T therapy technologies from the laboratory of John F. DiPersio, M.D., Ph.D. Wugen was founded based on technology licensed from Washington University. The partnership has enabled development of fratricide-resistant allogeneic CAR-T cell therapies for T-cell malignancies.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Wugen competitors and assessment

Company assessment

Direct peers

  • Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with multiple clinical-stage programs targeting hematologic malignancies and solid tumors. Both companies share the allogeneic off-the-shelf CAR-T approach using healthy donor-derived cells, making them direct competitors in the same regulatory and commercial landscape.
  • Fate Therapeutics: Fate Therapeutics develops off-the-shelf NK cell and T-cell therapies using iPSC-derived and engineered cell platforms. Its memory NK cell programs (including FT516 and FT576) directly compete with Wugen's WU-NK-101, and both companies target AML and B-cell malignancies with similar off-the-shelf strategies.
  • Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-T cell therapies using CRISPR-based gene editing technology. Both companies leverage CRISPR platforms for allogeneic CAR-T development, though Caribou focuses on B-cell malignancies with CB-010 while Wugen targets T-cell malignancies with WU-CART-007.
  • Precision Biosciences: Precision Biosciences develops allogeneic CAR-T therapies using ARCUS gene editing technology for hematologic malignancies and solid tumors. Its lead program PBCAR0191 and PBCAR20A target similar patient populations to Wugen's pipeline, making it a comparable competitor in the allogeneic CAR-T space.
  • Nkarta: Nkarta develops allogeneic NK cell therapies engineered with CAR constructs and other modifications for hematologic malignancies and autoimmune diseases. Its NKX019 (CD19-targeted NK) and NKX101 programs compete directly with Wugen's memory NK cell approach for hematologic cancer indications.
  • Cellectis: Cellectis is a clinical-stage allogeneic CAR-T developer using TALEN gene editing technology. Both companies pursue fratricide-resistant approaches and target T-cell malignancies, with Cellectis's UCART7 being a direct competitor to Wugen's WU-CART-007 in T-ALL.
  • Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies including CAR-T and NK cell programs targeting hematologic malignancies and solid tumors. Its multiplexed gene editing platform is comparable to Wugen's Moneta platform for off-the-shelf cell therapy manufacturing.

Broad incumbents

  • CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company developing both autologous (CASGEVY, approved for sickle cell disease) and allogeneic CAR-T cell therapies. Its CTX112 program targets B-cell malignancies, representing a broader gene editing player with adjacent allogeneic CAR-T ambitions.
  • Editas Medicine: Editas Medicine is a clinical-stage gene editing company developing CRISPR-based therapies, including EDIT-301 for sickle cell disease and other hematologic indications. While not focused on allogeneic CAR-T, it represents an adjacent gene editing peer with overlapping platform technology.

Regional players

  • Adaptimmune: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors with Tecelra approved for synovial sarcoma. While focused on autologous TCR-T rather than allogeneic CAR-T, it represents a comparable clinical-stage cell therapy peer targeting hematologic and solid tumor indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Wugen social profiles

Digital presence

Wugen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wugen leadership team

Management profile

Number of profiles

Profiles10 records

Wugen funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wugen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wugen

What does Wugen do?

Wugen is a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for cancer treatment. Its lead candidate, Soficabtagene Geleucel (Sofi-cel / WU-CART-007), is an allogeneic CD7-targeted CAR-T therapy for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL), and WU-NK-101 is an allogeneic memory natural killer cell therapy for acute myeloid leukemia (AML) and solid tumors. The therapies are enabled by Wugen's proprietary CRISPR/Cas9 gene editing and the Moneta feeder cell-free manufacturing platform.

Is Wugen a public or private company?

Wugen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Wugen founded?

Wugen was founded in 2018. It employs 11 to 50 people.

Where is Wugen based?

Wugen is headquartered in St Louis, United States, in the North America region.

How does Wugen make money?

One revenue line is on record: cell Therapy Development and Commercialization.

Who are Wugen's main competitors?

Direct peers on record are Allogene Therapeutics, Fate Therapeutics, Caribou Biosciences, Precision Biosciences, Nkarta, Cellectis and Century Therapeutics. Broad incumbents are CRISPR Therapeutics and Editas Medicine. Adaptimmune is listed as a regional player.

Does Wugen have an API?

No public API is recorded for Wugen.

What industry is Wugen in?

Wugen's product category is Cell Therapy / Oncology Biotechnology. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAllotera Therapeutics Announces Opening of Minimal Residual Disease Cohort in the Pivotal T-RRex Study of Sofi-celAllotera Therapeutics opened the minimal residual disease-positive cohort in its pivotal T-RRex study of Sofi-cel, a CD7-targeted CAR-T therapy for relapsed or refractory T-ALL/T-LBL. The global Phase 2 study is conducted at 18 sites in the U.S. and Australia, aiming to determine if Sofi-cel can achieve MRD-negative remission.Stock TitanHCW Biologics Q2 Results: HCW9302 Phase 1 UpdateHCW Biologics reported preliminary positive clinical data for its lead autoimmune drug HCW9302 in a Phase 1 trial for alopecia areata, noting significant improvement in patient scores without serious side effects. The company also announced the re-acquisition of rights to commercial-ready molecules from AlloTera Therapeutics and raised approximately $5.6 million through private equity placements.PR NewswireCAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInThe CAR T-cell therapy market for Acute Lymphoblastic Leukemia (ALL) is projected to grow at a CAGR of 6.8% from 2026 to 2036, driven by advancements in emerging therapies and an expanding pipeline. Major contributors to this market include new therapies like Lasme-cel and WU-CART-007, alongside established players like Cellectis and Wugen, addressing the rising need for effective treatments for relapsed or refractory ALL cases. The ongoing innovations in CAR T-cell therapies are expected to redefine treatment standards and potentially enhance patient outcomes.openPR.comGlobal Trends Overview: The Rapid Evolution of the Electrocompetent Cells MarketThe Business Research Company published a market analysis forecasting the global electrocompetent cells market to reach $2.51 billion by 2030, driven by growth in gene therapy and biotechnology research. The report highlights key industry players such as Thermo Fisher Scientific and MaxCyte, noting specific developments like MaxCyte's partnership with Wugen Inc. for cancer treatment manufacturing.American City Business JournalsAllotera Therapeutics, formerly Wugen, raises $35 million for blood cancer trialAllotera Therapeutics, formerly known as Wugen, has raised $35 million in new funding to support a global clinical trial of its experimental therapy for aggressive blood cancers. The company has now raised more than $350 million since 2018. The new capital will advance the development of the company's cell therapy candidates toward potential regulatory approvals.BioWorldFinancings for July 9, 2026Biopharma and med-tech companies raised money in public or private financings on July 9, 2026, including Allotera, Bone Biologics, Leo Cancer, Lifeward, and Oramed. The list is provided by BioWorld.AlloteratxAllotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers – Alloteratx.comAllotera Therapeutics, formerly Wugen, closed a $35 million financing round comprising equity and venture debt, bringing total capital raised to $150 million. The funds will support the pivotal T-RRex trial of Soficabtagene Geleucel, an off-the-shelf CAR-T therapy for T-cell cancers. The company also entered a strategic partnership with Blood Cancer United.FinSMEsAllotera Therapeutics Raises $35M in FundingAllotera Therapeutics raised $35M in equity and venture debt, bringing its total funding to $150M. The company will use the funds to expand operations and R&D, including its lead CD7-targeted CAR-T therapy Sofi-cel. It also entered a strategic partnership with Blood Cancer United.Pulse 2.0Allotera Therapeutics Raises $35 Million To Advance Off-The-Shelf CAR-T TherapiesAllotera Therapeutics (formerly Wugen) announced the closing of a $35 million financing round, including equity, venture debt, and new investors, bringing its total capital raised to $150 million. The funding will support the global pivotal T-RREx clinical trial of Soficabtagene Geleucel (Sofi-cel), an allogeneic off-the-shelf CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The company also entered a strategic partnership with Blood Cancer United's Therapy Acceleration Program to access drug development expertise, clinical trial support, and patient education resources.Stock TitanAllotera closes $35M financing for CAR-T trialAllotera Therapeutics (formerly Wugen) has closed a $35 million financing round as an extension of its Series C, bringing total capital raised to $150 million, to advance its off-the-shelf CAR-T cell therapy Soficabtagene Geleucel (Sofi-cel) through the global pivotal T-RRex clinical trial for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The financing was led by Fidelity Management & Research Company with participation from Lightchain Capital, BioGenerator, and new investors including Blood Cancer United's Therapy Acceleration Program, while Banc of California provided the venture debt component. Allotera has also entered a strategic partnership with Blood Cancer United to access drug development expertise and clinical trial support as the company advances toward potential regulatory submission.